Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2017-12-21 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
BioArctic meddelar att Fas 2b studien med BAN2401 i patienter med tidig Alzheimers sjukdom fortsätter mot final analys vid 18 månader
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and is dated December 21, 2017. It announces the status of a clinical trial (Fas 2b study with BAN2401 for Alzheimer's disease), specifically noting that interim efficacy criteria at 12 months were not met, but the study will continue to the final 18-month analysis. The text concludes with a statement indicating that the information is being made public according to EU market abuse regulation and provides contact details. This structure—a brief announcement about a corporate/clinical event, often referencing future reports or results—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a formal announcement of a significant corporate event (clinical trial update), it fits best as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) as it is a mandatory disclosure under market rules. Given the content is a specific clinical trial update rather than standard quarterly financial highlights, RNS is a strong candidate, but ER often covers major operational milestones. However, the key indicator is the final paragraph: "Denna information är sådan information som BioArctic AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." This points strongly towards a general regulatory disclosure. Since the document is not a standard earnings report but a specific operational update mandated for disclosure, Regulatory Filings (RNS) is the most appropriate general category, although ER is often used for major operational news too. Given the specific nature of the announcement (clinical trial update, not financial results summary), RNS is safer than ER, but since it is a major operational update, ER is also plausible. Let's re-evaluate based on definitions. ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. RNS is 'General regulatory announcements and fallback category'. This fits perfectly as a mandatory disclosure of a material event under MAR. I will classify it as RNS.
2017-12-21 Swedish
BioArctic presents Nomination Committee and publishes financial calendar 2018
Report Publication Announcement Classification · 1% confidence The document is a press release titled "BioArctic presents Nomination Committee and publishes financial calendar 2018". It details the composition of the Nomination Committee for the upcoming 2018 Annual General Meeting (AGM) and lists future reporting dates, including the date for the 2018 AGM itself. While it mentions the AGM and future reports, the primary content is an announcement regarding the Nomination Committee structure and the publication of a financial calendar. This type of announcement, which communicates administrative updates and future scheduling rather than detailed financial results (ER/IR) or the AGM presentation itself (AGM-R), fits best under a general regulatory announcement or a specific announcement related to governance/shareholder matters. Since it announces the composition of the Nomination Committee (a governance body related to the AGM) and publishes a calendar, it is not a core financial report (10-K, IR, ER). It is not a DEF 14A (Remuneration) or DVA (Voting Results). Given the nature of announcing administrative/governance updates and future dates, it is most closely related to governance or a general regulatory announcement. However, the most specific category that covers the announcement of future reporting dates and administrative updates that don't fit elsewhere is often the Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since the document explicitly publishes a 'financial calendar' and details the Nomination Committee (which proposes AGM items), it is an announcement about future corporate events and governance structure. Because it is a press release announcing future dates and committee structure, and not the actual AGM materials or a specific financial report, 'RPA' (Report Publication Announcement) is a strong candidate as it announces future reports, or 'RNS' as a general regulatory announcement. Given the explicit mention of publishing the 'financial calendar 2018' and the AGM date, RPA is slightly more specific than RNS, but the content is heavily focused on governance setup (Nomination Committee). Since the document is short (4720 chars) and announces future reports, RPA is appropriate. However, the core subject is the Nomination Committee, which is governance-related. Let's re-evaluate: It is not a DEF 14A (Remuneration), nor a CGR (Governance Information, which usually details existing structure). It is an announcement of administrative steps leading up to the AGM. Given the dual nature (Nomination Committee + Calendar), RPA (announcing future reports) or RNS (general announcement) are the best fits. I will select RPA because it explicitly publishes the financial calendar, which is a form of reporting schedule announcement.
2017-11-09 English
BioArctic presenterar valberedning och offentliggör finansiell kalender 2018
Governance Information Classification · 1% confidence The document is a press release ("Pressmeddelande") dated November 9, 2017. The primary content announces the composition of the Nomination Committee (Valberedning) for the upcoming 2018 Annual General Meeting (AGM) and publishes the financial calendar for 2018. While it mentions the AGM date and the upcoming Annual Report (årsredovisning), the document itself is an announcement regarding corporate governance structure (Nomination Committee) and future reporting dates. This type of announcement, which details governance structure and shareholder-related processes leading up to a meeting, fits best under Governance Information (CGR) or potentially a general Regulatory Filing (RNS). Since it specifically details the composition and function of the body responsible for nominating directors and setting AGM agendas, CGR (Governance Information) is the most precise fit, although it also contains elements of an RPA (Report Publication Announcement) by listing future report dates. Given the focus on the Nomination Committee structure, CGR is prioritized over RPA or RNS.
2017-11-09 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for BioArctic covering the period January to September 2017. It contains comprehensive financial statements, management commentary (VD:s ord), project portfolio details, and notes. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2017
2017-11-08 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report January – September 2017' and contains comprehensive financial statements, including a financial summary, operating profit, cash flow, and notes to the financial reports. It covers a period shorter than a full fiscal year (nine months), which aligns perfectly with the definition of an Interim/Quarterly Report (IR). 9M 2017
2017-11-08 English
UTNYTTJANDE AV ÖVERTILLDELNINGSOPTION OCH AVSLUTANDE AV STABILISERINGSPERIOD
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated November 6, 2017, titled "UTNYTTJANDE AV ÖVERTILLDELNINGSOPTION OCH AVSLUTANDE AV STABILISERINGSPERIOD" (Exercise of Over-Allotment Option and Conclusion of Stabilization Period). It explicitly discusses the exercise of an over-allotment option related to a previous offering and the conclusion of market stabilization activities, referencing EU Market Abuse Regulation (MAR). This activity—managing the share price post-offering using stabilization mechanisms and exercising options related to the offering—falls under corporate financing and capital structure management. While it relates to an offering, the core announcement is about the finalization of the capital raising/offering mechanics (stabilization and option exercise). This aligns best with the 'Capital/Financing Update' category (CAP), as it details the conclusion of the post-IPO/offering capital management phase. It is not a general regulatory filing (RNS) because it is highly specific to a financing event, nor is it a general earnings release (ER) or an interim report (IR).
2017-11-06 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.